Charles Schwab Investment Management Inc. Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Charles Schwab Investment Management Inc. reduced its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 2.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 689,693 shares of the company’s stock after selling 15,130 shares during the period. Charles Schwab Investment Management Inc. owned about 0.80% of Syndax Pharmaceuticals worth $8,473,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Virtus ETF Advisers LLC lifted its position in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after purchasing an additional 827 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth $153,000. Guggenheim Capital LLC acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth $157,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Syndax Pharmaceuticals during the first quarter worth $162,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Syndax Pharmaceuticals during the first quarter worth $179,000.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 19,200 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.84, for a total value of $304,128.00. Following the completion of the sale, the director directly owned 191,763 shares of the company’s stock, valued at approximately $3,037,525.92. This represents a 9.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael A. Metzger sold 7,534 shares of the company’s stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total transaction of $69,990.86. Following the completion of the sale, the chief executive officer directly owned 298,661 shares of the company’s stock, valued at $2,774,560.69. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,230 shares of company stock valued at $684,527 in the last quarter. 4.10% of the stock is currently owned by insiders.

Syndax Pharmaceuticals Stock Down 3.6%

Syndax Pharmaceuticals stock opened at $15.66 on Tuesday. The company has a 50-day simple moving average of $10.97 and a 200-day simple moving average of $11.90. The firm has a market capitalization of $1.35 billion, a P/E ratio of -4.03 and a beta of 0.74. The company has a debt-to-equity ratio of 2.06, a quick ratio of 4.55 and a current ratio of 4.71. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $22.50.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.18. The business had revenue of $37.96 million during the quarter, compared to analyst estimates of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company’s quarterly revenue was up 984.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) earnings per share. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on SNDX. Guggenheim reissued a “buy” rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. The Goldman Sachs Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, July 10th. They issued a “buy” rating and a $18.00 price target on the stock. BTIG Research boosted their target price on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Scotiabank boosted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a “sector perform” rating in a research note on Tuesday, May 6th. Finally, B. Riley upgraded shares of Syndax Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Buy” and an average target price of $38.00.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).